Literature DB >> 21822821

Helicobacter pylori and gastric cancer.

Michael Rathbone1, Barrie Rathbone.   

Abstract

Gastric cancer remains a major cause of cancer death worldwide. The discovery of Helicobacter pylori Helicobacter pylori and its association with gastric cancer has opened up new insights into its pathogenesis. Gastric cancer pathogenesis is the result of a complex interplay between bacterial, host and environmental factors resulting in a step wise histological progression to neoplasia. H. pylori is a major factor in the early stages of cancer development and the mechanism of action of its virulence factors are being steadily unravelled. It is also now recognised that host genetic polymorphisms also play a complex role interacting synergistically with the bacterial virulence factors. The role of H. pylori in the causation of gastric cancer also raises the possibility of cancer prevention through screening and eradication, actions which may improve outcomes in high risk populations but which may not be cost-effective in areas of low risk. Ultimately, despite the vast improvements in knowledge, as yet there has not been a corresponding improvement in terms of gastric cancer survival rates.

Entities:  

Mesh:

Year:  2011        PMID: 21822821     DOI: 10.1007/978-3-642-03503-6_5

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  12 in total

Review 1.  Association between cadherin-17 expression and pathological characteristics of gastric cancer: a meta-analysis.

Authors:  Zi-Wen Long; Meng-Long Zhou; Jing-Wei Fu; Xian-Qun Chu; Ya-Nong Wang
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

2.  Symptom-histopathology relation in upper GI endoscopy.

Authors:  Emre Günay; Erkan Özkan; Hacı Mehmet Odabaşı; Hacı Hasan Abuoğlu; Cengiz Eriş; Mehmet Kamil Yıldız; Süleyman Atalay
Journal:  Ulus Cerrahi Derg       Date:  2013-09-01

3.  Gastric biopsies: the gap between evidence-based medicine and daily practice in the management of gastric Helicobacter pylori infection.

Authors:  Hala El-Zimaity; Stefano Serra; Eva Szentgyorgyi; Rajkumar Vajpeyi; Amir Samani
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

4.  Helicobacter pylori Eradication Therapy: Current Availabilities.

Authors:  M Gasparetto; M Pescarin; G Guariso
Journal:  ISRN Gastroenterol       Date:  2012-07-29

5.  CYP2E1 RsaI/PstI polymorphism and gastric cancer susceptibility: meta-analyses based on 24 case-control studies.

Authors:  Wenlei Zhuo; Liang Zhang; Yan Wang; Junjun Ling; Bo Zhu; Zhengtang Chen
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

6.  Prevalence of Helicobacter pylori vacA, cagA and iceA genotypes and correlation with clinical outcome.

Authors:  Guo-Chao Wei; Jing Chen; Ai-Yun Liu; Miao Zhang; Xiao-Jun Liu; Dan Liu; Jun Xu; Bing-Rong Liu; Hong Ling; Hua-Xing Wu; Ya-Ju DU
Journal:  Exp Ther Med       Date:  2012-09-11       Impact factor: 2.447

7.  Helicobacter Pylori "Test-and-Treat" Strategy for Management of Dyspepsia: A Comprehensive Review.

Authors:  Javier P Gisbert; Xavier Calvet
Journal:  Clin Transl Gastroenterol       Date:  2013-03-28       Impact factor: 4.488

8.  Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders.

Authors:  C J Carter
Journal:  J Pathog       Date:  2013-03-04

9.  Association of the virulence factors of Helicobacter pylori and gastric mucosal interleukin-17/23 mRNA expression in dyspeptic patients.

Authors:  Nader Bagheri; Ghorbanali Rahimian; Loghman Salimzadeh; Fatemeh Azadegan; Mahmoud Rafieian-Kopaei; Afshin Taghikhani; Hedayatollah Shirzad
Journal:  EXCLI J       Date:  2013-01-14       Impact factor: 4.068

Review 10.  Current evidences on XPC polymorphisms and gastric cancer susceptibility: a meta-analysis.

Authors:  Qiliu Peng; Zhiping Chen; Yu Lu; Xianjun Lao; Cuiju Mo; Ruolin Li; Xue Qin; Shan Li
Journal:  Diagn Pathol       Date:  2014-05-23       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.